Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glufosfamide in recurrent glioblastoma multiforme
NCT00014300Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2001
- Primary completion
- Sep 2001
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of glufosfamide in glioblastoma multiforme (GBM), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoints: Objective Response Rate and Progression-Free Survival at 6 months. Started Jan 2001; status: completed.
02
Drugs
glufosfamide
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00014300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00014300.